Recall: D-0551-2023

Class II - Potentially Harmful

Class IIClassification

2023-03-16Initiated

OngoingStatus

Northwind Pharmaceuticals LLCFirm

Product

Glimepiride Tablets, USP 2mg, packaged in a) 30-count bottles (NDC 51655-383-52), and b)90-count bottles (NDC 51655-383-26), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.

Reason

CGMP Deviations

Distribution

Nationwide with the United States

Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.